Angiodroid

About Angiodroid

Angiodroid S.p.A. is an Italian medical technology company established in July 2013, focusing on developing safer alternatives for angiographic procedures. The company was founded by Sebastiano Zannoli, who now serves as President, and Samuele Zannoli, the current CTO. Sebastiano Zannoli, a serial entrepreneur with extensive experience in managing medical device companies, identified the clinical need for a safer contrast agent, while Samuele Zannoli brought his background in physics and medical software development to the technical side of the venture. The company's primary focus is on the vast market for peripheral angiography, which conducts over 200 million procedures annually, with approximately 30% of patients at risk of contrast-induced acute kidney injury.

Angiodroid's core business revolves around the design, manufacturing, and global distribution of its flagship product, 'Angiodroid The CO2 Injector'. This system provides an automated method for using carbon dioxide (CO2) as a contrast medium, a biocompatible gas that eliminates the risk of nephrotoxicity and allergic reactions associated with traditional iodinated contrast media. The business model includes selling the patented injector and associated single-use kits through a network of national distributors and partnerships with major MedTech companies like Siemens Healthineers and Philips. The company's clients are hospitals and clinics with departments in interventional radiology, vascular surgery, and interventional cardiology.

The Angiodroid CO2 Injector is engineered to resolve the shortcomings of manual CO2 injection, a practice that lacked procedural repeatability and carried risks of air contamination. The device offers a fully automated, digital system that precisely controls the volume and pressure of the injected medical-grade CO2, ensuring procedural safety and consistency. Key features include a touchscreen interface, wireless remote control to reduce staff X-ray exposure, a built-in pressure sensor for performance monitoring, and rapid reloading capabilities. The system is particularly beneficial for patients with pre-existing conditions such as renal failure, diabetes, or allergies to iodine-based contrast agents. Since its inception, Angiodroid has secured over $10 million in funding from investors including CDP Venture Capital, Air Liquide's venture arm ALIAD, and Italian Angels for Growth, which has fueled its international expansion into more than 55 countries. The device has received CE marking and other international authorizations, though its 510(k) application in the U.S. was withdrawn in 2015 due to regulatory questions regarding CO2 gas itself, not the device.